Filing Details
- Accession Number:
- 0001564590-21-006355
- Form Type:
- 13G Filing
- Publication Date:
- 2021-02-17 15:46:31
- Filed By:
- Quested Robert
- Company:
- Silence Therapeutics Plc
- Filing Date:
- 2021-02-17
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Robert Quested | 7,620,279 | 0 | 7,620,279 | 0 | 7,620,279 | 8.5% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ) *
| Silence Therapeutics plc |
| (Name of Issuer)
|
| Ordinary Shares, par value £0.05 per share |
| (Title of Class of Securities)
|
| G8128Y157 |
| (Cusip Number)
|
| December 31, 2020 |
| (Date of Event which Requires Filing of this Statement)
|
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following pages)
Page 1 of 5 Pages
13G
| CUSIP No. G8128Y157 |
| ||||
| 1 | NAMES OF REPORTING PERSONS
Robert Quested | ||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ☐ (b) ☐
| ||||
| 3 | SEC USE ONLY
| ||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Gibraltar | ||||
| NUMBER OF
SHARES BENEFICIALLY OWNED BY
EACH
REPORTING PERSON WITH | 5 | SOLE VOTING POWER
7,620,279 | |||
| 6 | SHARED VOTING POWER
0 | ||||
| 7 | SOLE DISPOSITIVE POWER
7,620,279 | ||||
| 8 | SHARED DISPOSITIVE POWER
0 | ||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,620,279 | ||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐
| ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.5% | ||||
| 12 | TYPE OF REPORTING PERSON (See Instructions)
IN | ||||
|
|
|
|
| ||
Page 2 of 5 Pages
Item 1. Issuer
(a) Name of Issuer:
Silence Therapeutics plc (the “Company”)
(b) Address of Issuer’s Principal Executive Offices:
72 Hammersmith Road
London W14 8TH
United Kingdom
Item 2. Identity and Background
Title of Class of Securities and CUSIP Number (Items 2(d) and (e))
This statement relates to ordinary shares, par value £0.05 per share (the “Shares”), of the Company. The CUSIP number of the Shares is G8128Y157.
Name of Persons Filing, Address of Principal Business Office and Citizenship (Items 2(a), (b) and (c))
This statement is filed by Robert Quested (the “Reporting Person”).
The address of the Reporting Person is 65 The Anchorage, Rosia Road, Gibraltar GX11 1AD.
Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is an Entity Specified in (a) - (k):
Not applicable.
Item 4. Ownership
The percentages used herein and in the rest of this Schedule 13G are calculated based upon 89,381,913 Shares issued and outstanding as of February 4, 2021, as disclosed in the Company’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on February 8, 2021.
|
| (a) | Amount beneficially owned: 7,620,279Shares |
|
| (b) | Percent of class: 8.5% |
|
| (c) | (i) Sole power to vote or direct the vote: 7,620,279 |
(ii) Shared power to vote or direct the vote: 0
(iii) Sole power to dispose or direct the disposition: 7,620,279
(iv) Shared power to dispose or direct the disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be a beneficial owner of more than five percent of the class of securities, check the following: ☐
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Page 3 of 5 Pages
|
|
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
Not applicable.
|
|
Page 4 of 5 Pages
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: February 17, 2021
Robert Quested
|
| By: | /s/ Robert Quested |
|
|
|
|
| |
|
| Name: Robert Quested |
| |
|
|
|
| |
Page 5 of 5 Pages